Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.
about
Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKLNotch signaling deregulation in multiple myeloma: A rational molecular targetReceptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patientsTumor-expressed adrenomedullin accelerates breast cancer bone metastasis.WITHDRAWN: Cardamonin Inhibits Osteoclastogenesis Induced by Tumor Cells Through Interruption of the Signaling Pathway Activated by Receptor Activator of NF-κB Ligand.Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKLEmbelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathwayInhibition of BDNF in multiple myeloma blocks osteoclastogenesis via down-regulated stroma-derived RANKL expression both in vitro and in vivo.RANKL signaling and osteoclastogenesis is negatively regulated by cardamoninButein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signalingPlumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signalingMultiple myeloma/hypercalcemia.Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.Treatment strategies for bone disease.Mechanisms of multiple myeloma bone disease.Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma.Role of denosumab in breast cancer.Soluble molecules and bone metabolism in multiple myeloma: a review.RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines.Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow.Notch signaling drives multiple myeloma induced osteoclastogenesis.In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma.Melphalan modifies the bone microenvironment by enhancing osteoclast formation.Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.Functional osteoclast-like transformation of cultured human myeloma cell lines.RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases
P2860
Q24632345-2E59D196-3AC7-4C7E-BABA-6357207781A4Q26797283-301973AE-C02F-47E3-BA26-D2C8E13E2DC3Q28740575-E3BAF1C9-B3F3-4959-A96E-91C75A796143Q30301242-F79C6CE7-99A0-4D4B-95A6-3273C81E5940Q34241611-370C04DA-41FA-4C06-BFE0-2A217656CFB7Q34267974-24884AA3-AF5E-4826-B593-60A35543D879Q34279869-ABECD913-6434-40E3-ACBD-8C71250C26F5Q34450321-CA166772-ACB0-4A11-A606-1F87B231092FQ34731280-E9CF27E9-A60E-4049-AF3C-51B9A66E705FQ35511177-C15D8EEA-1876-4F62-81EE-3E4B00C0F5D2Q35751362-94C0FBDC-9C2E-4A31-8B8F-77F21C9F0FE1Q35901084-E7B30F6B-398F-4DD6-93EF-EB2A6ACF4164Q36147288-C77BE305-E7B7-48D1-A4A5-65CE812E4670Q36860987-84354596-B7D5-4DC3-9BD7-E2E4AC2B4C5EQ36902828-80D08A84-30B4-4A78-9B75-6E585C504C5DQ37056408-D22691CE-2DEE-4F12-B03A-E01B5FBE63B5Q37118787-57AC77A6-B72D-42D1-81B7-4D780E254DBFQ37571986-B21A6D7A-C9D2-4DB9-9C0F-17032DF28978Q37998401-3C9B0D1F-B817-4CC4-9E3B-691F4110C192Q38804090-06146ADB-9D22-4263-B6DC-EF30F0DF7061Q38855010-A3C86640-44A2-4EEA-BC56-359130385AB0Q38953233-E95A8013-2A8C-4FCC-9BDA-F7C9BE2B119DQ40215805-5A82505A-D9A5-4766-95BC-B1686CD4415FQ42366597-9B70488E-1827-4FB2-9A9B-DEB9A22A0AEBQ43965394-80D7B99B-FA3E-41D1-A256-8E15AC188646Q54644133-098FDA8B-1636-4703-81C0-8BFFBD9EB2AAQ57904702-2873A008-BA5D-49AE-80C1-AA808502A51C
P2860
Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Myeloma cells can directly con ...... way of osteoclast stimulation.
@en
type
label
Myeloma cells can directly con ...... way of osteoclast stimulation.
@en
prefLabel
Myeloma cells can directly con ...... way of osteoclast stimulation.
@en
P2093
P2860
P1476
Myeloma cells can directly con ...... hway of osteoclast stimulation
@en
P2093
J M W Quinn
J W Sentry
M Cole-Sinclair
P2860
P304
P356
10.1111/J.1365-2141.2004.05018.X
P407
P577
2004-07-01T00:00:00Z